Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 1,454,220 |
|
|||||
| News | - | ||||||
| Day High | 195.86 | Low High |
|||||
| Day Low | 192.75 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | BIIB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.51 | -0.26% | 193.60 | 17:20:15 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 193.34 | 192.75 | 195.86 | 193.18 | 194.11 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 35,850 | 1,454,220 | $ 194.06 | $ 282,209,889 | - | 189.44 - 319.76 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:14:34 | 45 | $ 193.50 | USD |
Biogen (BIIB) Options Flow Summary
Biogen Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 28.08B | 145.36M | - | 9.84B | 1.16B | 7.99 | 24.18 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Biogen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIIB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 195.45 | 197.73 | 189.44 | 193.06 | 1,277,259 | -1.85 | -0.95% |
| 1 Month | 216.15 | 217.57 | 189.44 | 203.22 | 1,157,352 | -22.55 | -10.43% |
| 3 Months | 245.98 | 251.99 | 189.44 | 218.67 | 1,222,122 | -52.38 | -21.29% |
| 6 Months | 256.34 | 268.74 | 189.44 | 231.34 | 1,145,158 | -62.74 | -24.48% |
| 1 Year | 293.99 | 319.76 | 189.44 | 254.72 | 1,094,207 | -100.39 | -34.15% |
| 3 Years | 260.68 | 468.2499 | 187.16 | 266.42 | 1,228,294 | -67.08 | -25.73% |
| 5 Years | 228.27 | 468.2499 | 187.16 | 269.59 | 1,384,239 | -34.67 | -15.19% |
Biogen Description
| Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021. |
